0001178913-21-000810.txt : 20210331 0001178913-21-000810.hdr.sgml : 20210331 20210301060828 ACCESSION NUMBER: 0001178913-21-000810 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evogene Ltd. CENTRAL INDEX KEY: 0001574565 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 13 GAD FEINSTEIN STREET STREET 2: PARK REHOVOT P.O.B 2100 CITY: REHOVOT STATE: L3 ZIP: 76121 BUSINESS PHONE: 97289311900 MAIL ADDRESS: STREET 1: 13 GAD FEINSTEIN STREET STREET 2: PARK REHOVOT P.O.B 2100 CITY: REHOVOT STATE: L3 ZIP: 76121 CORRESP 1 filename1.htm
 
Evogene Ltd.
13 Gad Feinstein Street,
Park Rehovot P.O.B 2100
Rehovot L3 76121 Israel

March 1, 2021

Via EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, D.C.  20549

Attn: Jason Drory

Re:          Evogene Ltd.
Registration Statement on Form F-3
Filed February 19, 2021
File No. 333- 253300

Ladies and Gentlemen:
 
Evogene Ltd. (the “Company”) hereby requests acceleration of the effectiveness of the above-referenced registration statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on March 3, 2021, at 9:00 a.m., Eastern Time, or as soon thereafter as is practicable.

The Company understands that the Commission will consider this request for acceleration of the effective date of the above-referenced registration statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the above-referenced registration statement.
 
 
Very truly yours,

EVOGENE LTD.
  
       

By:
/s/ Dorit Kreiner  
    Dorit Kreiner  
   
Chief Financial Officer
  

cc:          Oded Har-Even, Esq.
Howard E. Berkenblit, Esq.